{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T21:22:11Z","timestamp":1789420931095,"version":"build-2803163510"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2015,4,1]],"date-time":"2015-04-01T00:00:00Z","timestamp":1427846400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100008173","name":"Intermountain Research and Medical Foundation","doi-asserted-by":"publisher","award":["ID0ETMAE11"],"award-info":[{"award-number":["ID0ETMAE11"]}],"id":[{"id":"10.13039\/100008173","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Diagn Ther"],"published-print":{"date-parts":[[2015,4]]},"DOI":"10.1007\/s40291-015-0137-4","type":"journal-article","created":{"date-parts":[[2015,4,22]],"date-time":"2015-04-22T03:41:06Z","timestamp":1429674066000},"page":"131-138","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["A Possible Mechanistic Link Between the CYP2C19 Genotype, the Methadone Metabolite Ethylidene-1,5-Dimethyl-3,3-Diphenylpyrrolidene (EDDP), and Methadone-Induced Corrected QT Interval Prolongation in a Pilot Study"],"prefix":"10.1007","volume":"19","author":[{"given":"John F.","family":"Carlquist","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David E.","family":"Moody","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacey","family":"Knight","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric G.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenfang B.","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A.","family":"Huntinghouse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey S.","family":"Rollo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynn R.","family":"Webster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey L.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,4,23]]},"reference":[{"key":"137_CR1","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1046\/j.1360-0443.2000.951778.x","volume":"95","author":"D Zador","year":"2000","unstructured":"Zador D, Sunjic S. Deaths in methadone maintenance treatment in New South Wales, Australia 1990\u20131995. Addiction. 2000;95:77\u201384.","journal-title":"Addiction."},{"key":"137_CR2","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1300\/J126v02n03_06","volume":"2","author":"D Wagner-Servais","year":"2003","unstructured":"Wagner-Servais D, Erkens M. Methadone-related deaths associated with faulty induction procedures. J Maint Addic. 2003;2:57\u201367.","journal-title":"J Maint Addic."},{"key":"137_CR3","doi-asserted-by":"crossref","first-page":"501","DOI":"10.7326\/0003-4819-137-6-200209170-00010","volume":"137","author":"MJ Krantz","year":"2002","unstructured":"Krantz MJ, Lewkowiez L, Hays H, Woodroffe MA, Robertson AD, Mehler PS. Torsade de pointes associated with very-high-dose methadone. Ann Intern Med. 2002;137:501\u20134.","journal-title":"Ann Intern Med."},{"key":"137_CR4","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1136\/hrt.2006.100180","volume":"93","author":"S Fanoe","year":"2007","unstructured":"Fanoe S, Hvidt C, Ege P, Jensen GB. Syncope and QT prolongation among patients treated with methadone for heroin dependence in the city of Copenhagen. Heart. 2007;93:1051\u20135.","journal-title":"Heart."},{"key":"137_CR5","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1159\/000081416","volume":"11","author":"I Maremmani","year":"2005","unstructured":"Maremmani I, Pacini M, Cesaroni C, Lovrecic M, Perugi G, Tagliamonte A. QTc interval prolongation in patients on long-term methadone maintenance therapy. Eur Addict Res. 2005;11:44\u20139.","journal-title":"Eur Addict Res."},{"key":"137_CR6","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1001\/archinte.166.12.1280","volume":"166","author":"GB Ehret","year":"2006","unstructured":"Ehret GB, Voide C, Gex-Fabry M, Chabert J, Shah D, Broers B, et al. Drug-induced long QT syndrome in injection drug users receiving methadone: high frequency in hospitalized patients and risk factors. Arch Intern Med. 2006;166:1280\u20137.","journal-title":"Arch Intern Med."},{"key":"137_CR7","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.jacc.2005.08.067","volume":"47","author":"SM Straus","year":"2006","unstructured":"Straus SM, Kors JA, De Bruin ML, van der Hooft CS, Hofman A, Heeringa J, et al. Prolonged QTc interval and risk of sudden cardiac death in a population of older adults. J Am Coll Cardiol. 2006;47:362\u20137.","journal-title":"J Am Coll Cardiol."},{"key":"137_CR8","doi-asserted-by":"crossref","first-page":"387","DOI":"10.7326\/0003-4819-150-6-200903170-00103","volume":"150","author":"MJ Krantz","year":"2009","unstructured":"Krantz MJ, Martin J, Stimmel B, Mehta D, Haigney MC. QTc interval screening in methadone treatment. Ann Intern Med. 2009;150:387\u201395.","journal-title":"Ann Intern Med."},{"key":"137_CR9","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1038\/sj.clpt.6100120","volume":"81","author":"CB Eap","year":"2007","unstructured":"Eap CB, Crettol S, Rougier JS, Schlapfer J, Sintra Grilo L, Deglon JJ, et al. Stereoselective block of hERG channel by (S)-methadone and QT interval prolongation in CYP2B6 slow metabolizers. Clin Pharmacol Ther. 2007;81:719\u201328.","journal-title":"Clin Pharmacol Ther."},{"key":"137_CR10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0735-1097(00)00716-6","volume":"36","author":"CE Chiang","year":"2000","unstructured":"Chiang CE, Roden DM. The long QT syndromes: genetic basis and clinical implications. J Am Coll Cardiol. 2000;36:1\u201312.","journal-title":"J Am Coll Cardiol."},{"key":"137_CR11","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1001\/archinternmed.2010.26","volume":"170","author":"N Ansermot","year":"2010","unstructured":"Ansermot N, Albayrak O, Schlapfer J, Crettol S, Croquette-Krokar M, Bourquin M, et al. Substitution of (R, S)-methadone by (R)-methadone: impact on QTc interval. Arch Intern Med. 2010;170:529\u201336.","journal-title":"Arch Intern Med."},{"key":"137_CR12","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.2165\/00003088-200241140-00003","volume":"41","author":"CB Eap","year":"2002","unstructured":"Eap CB, Buclin T, Baumann P. Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence. Clin Pharmacokinet. 2002;41:1153\u201393.","journal-title":"Clin Pharmacokinet."},{"key":"137_CR13","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1111\/j.1365-2044.2007.05129.x","volume":"62","author":"D Atkinson","year":"2007","unstructured":"Atkinson D, Dunne A, Parker M. Torsades de pointes and self-terminating ventricular fibrillation in a prescription methadone user. Anaesthesia. 2007;62:952\u20135.","journal-title":"Anaesthesia."},{"key":"137_CR14","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.1360-0443.2006.01668.x","volume":"102","author":"E Peles","year":"2007","unstructured":"Peles E, Bodner G, Kreek MJ, Rados V, Adelson M. Corrected-QT intervals as related to methadone dose and serum level in methadone maintenance treatment (MMT) patients: a cross-sectional study. Addiction. 2007;102:289\u2013300.","journal-title":"Addiction."},{"key":"137_CR15","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1002\/pds.1112","volume":"14","author":"EC Pearson","year":"2005","unstructured":"Pearson EC, Woosley RL. QT prolongation and torsades de pointes among methadone users: reports to the FDA spontaneous reporting system. Pharmacoepidemiol Drug Saf. 2005;14:747\u201353.","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"137_CR16","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1038\/sj.clpt.6100237","volume":"82","author":"ED Kharasch","year":"2007","unstructured":"Kharasch ED, Walker A, Isoherranen N, Hoffer C, Sheffels P, Thummel K, et al. Influence of CYP3A5 genotype on the pharmacokinetics and pharmacodynamics of the cytochrome P4503A probes alfentanil and midazolam. Clin Pharmacol Ther. 2007;82:410\u201326.","journal-title":"Clin Pharmacol Ther."},{"key":"137_CR17","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1742-7843.2010.00628.x","volume":"108","author":"Y Chang","year":"2011","unstructured":"Chang Y, Fang WB, Lin SN, Moody DE. Stereo-selective metabolism of methadone by human liver microsomes and cDNA-expressed cytochrome P450s: a reconciliation. Basic Clin Pharmacol Toxicol. 2011;108:55\u201362.","journal-title":"Basic Clin Pharmacol Toxicol."},{"key":"137_CR18","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1124\/jpet.106.117580","volume":"321","author":"RA Totah","year":"2007","unstructured":"Totah RA, Allen KE, Sheffels P, Whittington D, Kharasch ED. Enantiomeric metabolic interactions and stereoselective human methadone metabolism. J Pharmacol Exp Ther. 2007;321:389\u201399.","journal-title":"J Pharmacol Exp Ther."},{"key":"137_CR19","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.clpt.2005.08.011","volume":"78","author":"S Crettol","year":"2005","unstructured":"Crettol S, Deglon JJ, Besson J, Croquette-Krokkar M, Gothuey I, Hammig R, et al. Methadone enantiomer plasma levels, CYP2B6, CYP2C19, and CYP2C9 genotypes, and response to treatment. Clin Pharmacol Ther. 2005;78:593\u2013604.","journal-title":"Clin Pharmacol Ther."},{"key":"137_CR20","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.clpt.2006.09.012","volume":"80","author":"S Crettol","year":"2006","unstructured":"Crettol S, Deglon JJ, Besson J, Croquette-Krokar M, Hammig R, Gothuey I, et al. ABCB1 and cytochrome P450 genotypes and phenotypes: influence on methadone plasma levels and response to treatment. Clin Pharmacol Ther. 2006;80:668\u201381.","journal-title":"Clin Pharmacol Ther."},{"key":"137_CR21","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1124\/dmd.105.008904","volume":"34","author":"P He","year":"2006","unstructured":"He P, Court MH, Greenblatt DJ, von Moltke LL. Factors influencing midazolam hydroxylation activity in human liver microsomes. Drug Metab Dispos. 2006;34:1198\u2013207.","journal-title":"Drug Metab Dispos."},{"key":"137_CR22","doi-asserted-by":"crossref","first-page":"e19527","DOI":"10.1371\/journal.pone.0019527","volume":"6","author":"F Fonseca","year":"2011","unstructured":"Fonseca F, de la Torre R, Diaz L, Pastor A, Cuyas E, Pizarro N, et al. Contribution of cytochrome P450 and ABCB1 genetic variability on methadone pharmacokinetics, dose requirements, and response. PloS One. 2011;6:e19527.","journal-title":"PloS One."},{"key":"137_CR23","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1089\/omi.2012.0068","volume":"17","author":"SC Wang","year":"2013","unstructured":"Wang SC, Ho IK, Tsou HH, Liu SW, Hsiao CF, Chen CH, et al. Functional genetic polymorphisms in CYP2C19 Gene in relation to cardiac side effects and treatment dose in a methadone maintenance cohort. OMICS. 2013;17:519\u201326.","journal-title":"OMICS."},{"key":"137_CR24","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/ng.362","volume":"41","author":"A Pfeufer","year":"2009","unstructured":"Pfeufer A, Sanna S, Arking DE, Muller M, Gateva V, Fuchsberger C, et al. Common variants at ten loci modulate the QT interval duration in the QTSCD study. Nat Genet. 2009;41:407\u201314.","journal-title":"Nat Genet."},{"key":"137_CR25","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1038\/ng.361","volume":"41","author":"C Newton-Cheh","year":"2009","unstructured":"Newton-Cheh C, Johnson T, Gateva V, Tobin MD, Bochud M, Coin L, et al. Genome-wide association study identifies eight loci associated with blood pressure. Nat Genet. 2009;41:666\u201376.","journal-title":"Nat Genet."},{"key":"137_CR26","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1517\/17425255.2013.783567","volume":"9","author":"DE Moody","year":"2013","unstructured":"Moody DE. Metabolic and toxicological considerations of the opioid replacement therapy and analgesic drugs: methadone and buprenorphine. Expert Opin Drug Metab Toxicol. 2013;9:675\u201397.","journal-title":"Expert Opin Drug Metab Toxicol."},{"key":"137_CR27","unstructured":"Intermountain Health Care, Inc. Methadone monitoring for insights into adverse events (MEMORIES) [ClinicalTrials.gov identifier NCT01191242]. US National Institutes of Health, ClinicalTrials.gov. http:\/\/www.clinicaltrials.gov . Accessed 25 Mar 2015."},{"key":"137_CR28","unstructured":"CredibleMeds\u00ae. Combined list of drugs that prolong QT and\/or cause torsades de pointes (TDP). http:\/\/www.crediblemeds.org\/pdftemp\/pdf\/CompositeList.pdf . Accessed 25 Mar 2015."}],"container-title":["Molecular Diagnosis & Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40291-015-0137-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40291-015-0137-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40291-015-0137-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T18:23:44Z","timestamp":1559499824000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40291-015-0137-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["137"],"URL":"https:\/\/doi.org\/10.1007\/s40291-015-0137-4","relation":{},"ISSN":["1177-1062","1179-2000"],"issn-type":[{"value":"1177-1062","type":"print"},{"value":"1179-2000","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,4]]}}}